Arikayce uk market?

See the DrugPatentWatch profile for Arikayce

What is Arikayce, and what does it treat?

Arikayce (amikacin liposome inhalation suspension) is an inhaled antibiotic used for the treatment of adults with refractory Mycobacterium avium complex (MAC) lung disease. It is specifically for cases where the condition has not adequately responded to guideline-based multidrug therapy. [1][2]

Is Arikayce available in the UK?

Yes. Arikayce is marketed in the UK for the indicated population (refractory MAC lung disease). Availability is tied to the UK’s regulatory and reimbursement decisions for that indication. [1]

What kind of UK pricing/reimbursement should patients or providers expect?

UK costs and patient access depend on the specific commissioning and reimbursement route used for the product and indication (which can differ by NHS pathway and local arrangements). Public, up-to-date figures are typically handled through UK medicine price/access databases and NHS procurement channels rather than a single universally published “UK price.” [1]

Who sells it in the UK, and where is it supplied from?

Arikayce is supplied under the product’s marketing authorization in the UK by the company holding the UK authorization/brand distribution for the drug. The exact UK supply entity and distribution details are usually shown on the UK product prescribing information and local medicine listings. [1]

What evidence supports use in the UK indication?

UK use is based on the clinical evidence for Arikayce in refractory MAC lung disease, including trials used by regulators to support the indication and dosing approach. Clinicians typically use it within an overall multidrug regimen for MAC, aligned with guideline and regulatory labeling for refractory cases. [1][2]

What is the UK dosing and administration like?

Arikayce is inhaled (delivered via a nebulizer device) as an add-on inhaled amikacin liposome regimen used alongside other MAC therapies, with administration requirements and monitoring defined in the UK prescribing information. [1][2]

What side effects are UK patients likely to ask about?

Common patient concerns for inhaled amikacin products generally include respiratory tolerability (such as cough and hoarseness) and potential aminoglycoside-related risks, with risk/benefit assessed against the refractory MAC setting. The specific side-effect profile and monitoring instructions come from the UK label. [1][2]

Sources

1. EMA. Arikayce (amikacin liposome inhalation suspension) product information (EU/related documentation)
   
2. FDA. Arikayce prescribing information (for clinical context on refractory MAC indication)